Participating Companies

Abliva Ab [ABLI:ST] SKr203 MM MCap
Fo­cused on rare and se­vere pri­mary mi­to­chon­drial dis­eas­es (PMD). KL1333, a NAD+ reg­u­la­tor, to ac­cel­er­ate in­to piv­o­tal studies in 2H21 based on pos­i­tive FDA feed­back; ini­tial re­sults from Ph1b in PMD pa­tients exp. in 1Q21. NV354, an en­er­gy re­place­ment ther­a­py for Leigh Syn­drome, in IND-en­abling studies. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] $32 MM MCap
Launched DSU­VIA (sufen­tanil sublin­gual tablet 30 mcg) in the US in 2019 for acute pain se­vere enough to re­quire opi­oid anal­gesic (adult pa­tients in cer­ti­fied med­i­cal­ly su­per­vised health­care sett­ings). Al­so de­vel­op­ing Za­lvi­so (Ph 3 com­plet­ed) in the US as an in­no­va­tive pa­tient-con­trolled anal­ge­sia sys­tem for mod­er­ate-to-se­vere acute pain in med­i­cal­ly su­per­vised sett­ings. [more in­for­ma­tion]
Affibody
Lead can­di­date Izok­ibep, sup­port­ed by part­n­er­ship with Ace­lyrin, is an IL-17 in­hibi­tor with mul­ti­ple Ph2 pro­grams in progress (PSO, axS­pA, uvei­tis, HS, PsA). ACR50 pri­mary end­point met for 16 wk da­ta in PsA. First pa­tient dosed in piv­o­tal Phase 2b trial for uvei­tis filed in 1H2022 with 24 wk da­ta ex­pect­ed in 2023. On­go­ing re­la­tion­ship with In­ma­gene in Chi­na. [more in­for­ma­tion]
Affimed N.V. [AFMD] $299 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) en­rolling in a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
Alladapt Immunotherapeutics, Inc.
De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is cur­rent­ly in a Ph 1/2 clin­i­cal trial and an OLE study, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves as Al­la­dapt’s CEO. [more in­for­ma­tion]
Aptorum Group [APM] $41 MM MCap
Hong Kong based, US list­ed com­pany fo­cused on gen­er­at­ing late stage clin­i­cal can­di­dates by de­vel­op­ing al­ready ap­proved drugs for new or­phan in­di­ca­tions, as well as in­fec­tious dis­eas­es. [more in­for­ma­tion]
AsclepiX Therapeutics
Oph­thal­mol­o­gy com­pany us­ing com­pu­ta­tio­n­al bi­ol­o­gy to iden­ti­fy po­tent pep­tide reg­u­la­tors of vas­cu­lar home­os­ta­sis. The lead clin­i­cal can­di­date, in­te­grin reg­u­lat­ing pep­tide AX­T107 (ger­sizan­gi­tide), has a nov­el mech­anism of ac­tion that in­hibits neo­vas­cu­lariza­tion, re­duces vas­cu­lar perme­a­bil­i­ty and sup­press­es in­flam­ma­tion. In June 2020, Per­cep­tive Xon­toge­ny Ven­ture Fund led the $35 mil­lion Se­ries A fi­nanc­ing with par­ti­ci­pa­tion from ex­ist­ing in­ves­tors Rapha Cap­i­tal Ma­n­age­ment and Bar­er & Son Cap­i­tal. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] $82 MM MCap
A pi­oneer in the de­vel­op­ment of a new class of po­tent, oral core in­hibi­tor drug can­di­dates, As­sem­b­ly Bio’s ap­proach aims to break the com­plex vi­ral re­pli­ca­tion cy­cle of HBV to free pa­tients from a life­time of ther­a­py. As­sem­b­ly Bio’s strat­e­gy to­ward cure in­cludes a lead­ing port­fo­lio of more po­tent, next-gen­er­a­tion core in­hibi­tors, proof-of-con­cept com­bi­na­tion studies and a re­search pro­gram fo­cused on the dis­cov­ery of nov­el HBV tar­gets, in­clud­ing cc­cD­NA dis­rup­tors and two other undis­closed mech­anisms. In 202 [more in­for­ma­tion]
AxoGen [AXGN] $503 MM MCap
Glob­al lead­er in de­vel­op­ment and mar­ket­ing of in­no­va­tive sur­g­i­cal so­lu­tions for the pe­ripher­al nerve in­jury mar­ket. Gui­dance for 2021 rev­enue is $127M-$129M with ex­pect­ed 2021 Gross Mar­gin re­main­ing above 80%. Lead prod­uct Avance Nerve Graft is a pro­cessed, hu­man al­lo­graft for bridg­ing nerve gaps of up to 70 mm. [more in­for­ma­tion]
Be Biopharma
Be Bio­phar­ma is a lead­er in de­vel­op­ing B cells as medicines, treat­ing dis­ease with the hu­man body’s na­tive pro­tein fac­to­ries. We pre­cise­ly en­gi­neer B cells to har­ness their in­trin­sic drug-like prop­er­ties – re­mark­able pro­tein pro­duc­tion, se­lec­tive tis­sue tar­get­ing, and fine con­trol of their cel­lu­lar en­vi­ron­ment – to forge a new cat­e­go­ry of cell ther­a­py. Be Bio was found­ed in Oc­to­ber 2020 by Long­wood Fund with a $52 mil­lion Se­ries A in­vest­ment led by At­las Ven­tures and RA Cap­i­tal, joined by Al­ta Part­n­ers and [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] $288 MM MCap
Com­mer­cial-stage, fo­cused on neu­ro­log­i­cal & neu­ropsychi­a­tric dis­eas­es; CGRP re­cep­tor an­ta­g­on­ist, glu­ta­mate mo­d­u­la­tion, and MPO plat­forms. NURTEC® ODT ap­proved 1Q20 acute treat­ment of mi­graine and 1Q21 pre­ven­tive treat­ment of mi­graine; $136m 3Q21 rev­enues. [more in­for­ma­tion]
BioShin
Whol­ly owned sub­si­diary of Bio­haven Phar­ma­ceu­ti­cals. Shang­hai-based, led by ex-BMY ex­ec and Bio­haven’s Chief of Corp Strat­e­gy & BD, Don­nie Mc­Grath, Bioshin aims to de­vel­op and com­mer­cial­ize Bio­haven’s late-stage mi­graine and neu­rol­o­gy port­fo­lio in Chi­na and other APAC mar­kets. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] $38 MM MCap
Launched EVOMELA® (mel­pha­lan for in­jec­tion, mul­ti­ple myelo­ma) in Au­gust '19, on­ly mel­pha­lan com­mer­cial­ly avai­l­able in Chi­na: $7.1M 2Q21 rev­enues/guid­ing FY 2020 of over 80% growth. Co-com­mer­cial as­set CNCT-19/CD19 CAR-T (part­nered w/ Ju­ven­tas): on­go­ing Ph 2 trials in B-NHL and B-ALL. Dosed 1st pa­tient in Ph 1 study for CID-103 (an­ti-CD38 mAb) in EU in June 2021. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] $1,311 MM MCap
Ca­t­alyst's New Drug Ap­pli­ca­tion for FIR­DAPSE® (am­i­fam­pri­dine) Tablets 10 mg for the treat­ment of adults with Lam­bert-Ea­ton myas­thenic syn­drome ("LEMS") was ap­proved in 2018 by the U.S. Food & Drug Ad­min­is­tra­tion ("FDA"), and FIR­DAPSE is com­mer­cial­ly avai­l­able in the Unit­ed States as a treat­ment for adults with LEMS. Fur­ther, Ca­na­da's na­tio­n­al health­care reg­u­la­to­ry agen­cy, Health Ca­na­da, has ap­proved the use of FIR­DAPSE for the treat­ment of adult pa­tients in Ca­na­da with LEMS. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Om­ni­fo­cal con­tact lens pres­by­opia 510k sub­mis­sion and my­opia pro­gres­sion clin­i­cal da­ta in 2H2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Corium, Inc.
The Com­pany’s CNS busi­ness has the po­ten­tial for two prod­uct ap­pro­vals within 1 year, pro­vid­ing a com­bined peak sales po­ten­tial of >$500M. The Com­pany’s 20+ year trans­der­mal CD­MO busi­ness pro­vides unique end-to-end ca­pa­bil­i­ties, ex­clu­sive con­tracts with lead­ing com­pa­nies, and a grow­ing rev­enue po­ten­tial of >$100M. [more in­for­ma­tion]
Delcath Systems, Inc. [DCTH] $29 MM MCap
In­ter­ven­tio­n­al on­col­o­gy com­pany fo­cused on the treat­ment of pri­mary and me­tastat­ic liv­er can­cers. Com­pany’s pro­pri­e­tary per­cu­ta­neous he­p­at­ic per­fu­sion (PHP) sys­tem is de­signed to ad­min­is­ter high-dose che­mother­a­py to the liv­er while con­trolling sys­temic ex­po­sure and as­so­ci­at­ed side ef­fects. In the U.S., the PHP sys­tem is be­ing de­vel­oped un­der the tra­de­name HEP­ZA­TO KIT or HEP­ZA­TO, and is con­sid­ered a com­bi­na­tion drug and de­vice prod­uct reg­u­lat­ed by the FDA. [more in­for­ma­tion]
DURECT Corporation [DRRX] $132 MM MCap
Lead com­pound, lar­su­cos­terol, has been grant­ed FDA Fast Track Desig­na­tion for al­co­hol-as­so­ci­at­ed he­p­ati­tis (AH), re­sult­ed in 100% sur­vi­val in AH in Phase 2a study, and is en­rolling a Phase 2b trial in AH. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] $52 MM MCap
Fo­cused on de­vel­op­ing nov­el ther­a­pies for the treat­ment of pros­tate can­cer. ES­SA’s lead clin­i­cal can­di­date, EPI-7386 is an in­vesti­ga­tio­n­al, high­ly-se­lec­tive, oral, small molecule in­hibi­tor of the N-ter­mi­nal do­main of the an­dro­gen re­cep­tor, with Ph 1 monother­a­py da­ta ex­pect­ed in 1H 2022. The com­pany has al­so estab­lished clin­i­cal col­lab­o­ra­tions with JNJ, Astel­las, and Bay­er. [more in­for­ma­tion]
Galera Therapeutics [GRTX] $46 MM MCap
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cus­ing on trans­form­ing ra­dio­ther­a­py in can­cer. Fi­nal da­ta with 1 year+ fol­low up on all pa­tients for GC4419 in pan­cre­at­ic can­cer an­nounced in 3Q21. To­p­line da­ta from GC4711 in NS­CLC ex­pect­ed in 1H22. To­p­line da­ta from GC4711 in NS­CLC ex­pect­ed in 1H22. [more in­for­ma­tion]
GENFIT SA [GNFT] $194 MM MCap
Ipsen li­censed lead can­di­date EL­A­TIVE (ela­fi­branor) for &eu­ro;120M up­front pay­ment, up to &eu­ro;360M in po­ten­tial mile­s­tones, and dou­ble-dig­it roy­al­ties (tiered up to 20%). See Phase 3 EL­A­TIVE en­roll­ment com­ple­tion in 1Q22 and Phase 1 clin­i­cal da­ta for ni­ta­zox­anide (acute chron­ic liv­er fail­ure) by 3Q22 [more in­for­ma­tion]
Geron Corporation [GERN] $899 MM MCap
Fo­cused on the de­vel­op­ment and po­ten­tial com­mer­cial­iza­tion of a first-in-class telom­erase in­hibi­tor, ime­tel­s­tat, in myeloid he­ma­to­log­ic ma­lig­nan­cies. Geron is cur­rent­ly con­duct­ing two on­go­ing reg­is­tra­tion-en­abling Ph 3 clin­i­cal trials: (i) IMerge Phase 3 in Low or In­ter­me­di­ate-1 risk myelodys­plas­tic syn­dromes, or low­er risk MDS, and (ii) IM­pactMF in In­ter­me­di­ate-2 or High-risk myelo­fi­bro­sis, or re­frac­to­ry MF. Geron ex­pects top-line re­sults for IMerge Phase 3 to be avai­l­able at the be­gin­n­ing of Jan­uary 2023. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €161 MM MCap
AT­AC plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. Lead prod­uct HDP-101, for blood can­cer, is ex­pect­ed to start clin­i­cal dev' end of 2021. Out-li­cens­ing the AT­AC tech­nol­o­gy us­ing the part­n­ers’ anti­bodies to cre­ate new AT­ACs and ex­pect long term in­come streams and ear­ly tech­nol­o­gy vali­da­tion. [more in­for­ma­tion]
Humanigen Inc. [HGEN] $20 MM MCap
re­sults of NIH Phase 2/3 study in COVID that may serve as ba­sis for EUA, BLA, or both in the U.S. ini­ti­a­tion and in­ter­im as­sess­ment of Phase 2/3 trial for pre­ven­tion/treat­ment of acute GVHD, ini­ti­a­tion of Phase 3 with CAR-T and pre­sen­ta­tion of top-line da­ta from some pa­tients at ASH 2022. [more in­for­ma­tion]
ImmuneSensor Therapeutics
Im­mu­ne­Sen­sor is a ther­a­peu­tic in­nate im­mu­ni­ty com­pany de­vel­op­ing drugs tar­get­ing the cGAS-ST­ING path­way for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany was co-found­ed by Dr. Zhi­jian “James” Chen of UTSW who won the 2019 Break-through prize and 2018 Lurie prize for the dis­cov­ery of the cGAS-ST­ING path­way. The com­pany pipe­line in­cludes a clin­i­cal stage ST­ING ag­on­ist, cur­rent­ly in monother­a­py and ICI com­bi­na­tion trial, with ex­pec­ta­tions to en­ter Phase 2 in 2H23. [more in­for­ma­tion]
Immunocore [IMCR] $2,028 MM MCap
Im­muno­core is a pi­oneer­ing, com­mer­cial-stage T cell re­cep­tor biotech­nol­o­gy com­pany work­ing to de­vel­op and com­mer­cial­ize a new gen­er­a­tion of trans­for­ma­tive medicines to ad­dress un­met needs in can­cer, in­fec­tion and au­toim­mune dis­ease, with the first TCR ther­a­peu­tic to re­ceive reg­u­la­to­ry ap­pro­val. [more in­for­ma­tion]
Impact Therapeutics Inc
IM­PACT and Jun­shi Bio­s­ciences estab­lished a 50:50 joint ven­ture that fo­cus­es on the de­vel­op­ment and com­mer­cial­iza­tion of Se­na­parib in Chi­na. The JV is cur­rent­ly con­duct­ing a Phase II piv­o­tal study and a Phase III study of Se­na­parib in ovarian can­cer third-line treat­ment and first-line main­te­nance treat­ment in Chi­na. [more in­for­ma­tion]
IN8bio, Inc. [INAB] $53 MM MCap
First com­pany to ad­vance ge­net­i­cal­ly-mod­i­fied gam­ma-del­ta T cells in­to clin­i­cal trials with its Del­tEx Plat­form, based on ex-vi­vo ex­pand­ed and ac­ti­vat­ed gam­ma-del­ta T cells. Two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials are un­der­way for lead prod­uct can­di­dates: INB-200 for new­ly di­ag­nosed glioblas­to­ma and INB-100 for acute leukemia. [more in­for­ma­tion]
Invetx
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] $1,554 MM MCap
De­vel­op­ing nov­el can­cer im­munother­a­pies based on tu­mor in­fil­trat­ing lym­pho­cytes (TIL) for the treat­ment of solid tu­mors. TIL ther­a­py is a high­ly per­so­n­al­ized ap­proach in which pa­tients re­ceive a one-time treat­ment with their own ex­pand­ed and re­ju­ve­nat­ed T-cells to treat can­cer. BLA ex­pect­ed in Au­gust 2022 fol­low­ing com­ple­tion of piv­o­tal study of Li­fileu­cel/LN-144 for treat­ment of Me­lano­ma. [more in­for­ma­tion]
Junshi Biosciences [1877.HK]
Has a di­ver­si­fied R&D pipe­line com­pris­ing over 21 drug can­di­dates with ther­a­peu­tic ar­eas cov­er­ing can­cer, metabolic, au­toim­mune, neu­ro­log­i­cal, and in­fec­tious dis­eas­es. Lead can­di­date, Tori­pal­imab (JS001), reached over 1B RMB in sales, and ex­pand­ed in­di­ca­tions in­to na­sopha­ryn­geal car­ci­no­ma/urothe­lial car­ci­no­ma. Other prod­uct types in­clude mon­o­clo­n­al anti­bodies, fu­sion pro­teins, anti­body-drug con­ju­gates, and small molecule drugs. With a com­bined 33,000L fer­men­ta­tion ca­pac­i­ty in two GMP-fa­cil­i­ties at Shang­hai [more in­for­ma­tion]
KBio
Cre­at­ing the new gen­er­a­tion of bi­o­log­ics us­ing its plant-based plat­form that has de­mon­s­trat­ed an abil­i­ty to cre­ate po­ten­tial­ly bet­ter anti­body drug can­di­dates at a frac­tion of the time and cost of cur­rent mam­malian cell-based anti­body plat­forms. The Com­pany is fo­cused on de­vel­op­ing nov­el prod­uct can­di­dates in two core ar­eas: 1) Anti­body ther­a­pies for ar­eas of high un­met need 2) Pan­dem­ic pre­pared­ness and re­sponse us­ing its plant-based pro­duc­tion sys­tem to rapid­ly cre­ate anti­bodies and vaccines. [more in­for­ma­tion]
Keros Therapeutics [KROS] $1,031 MM MCap
A lead­er in un­der­s­tand­ing the role of the TGF-Be­ta fam­i­ly of pro­teins that is a mas­ter reg­u­la­tor of RBC and platelet pro­duc­tion as well as the growth, re­pair and main­te­nance of mus­cle and bone. Lead pro­tein ther­a­peu­tic prod­uct can­di­date, KER-050, is be­ing de­vel­oped for the treat­ment of cy­tope­nias, in­clud­ing ane­mia and throm­bo­cy­tope­nia, in pa­tients with myelodys­plas­tic syn­drome (MDS) and myelo­fi­bro­sis, with ad­di­tio­n­al da­ta ex­pect­ed from Part 1 of Ph 2 study in MDS be­ing pre­sent­ed at ASH 2021. [more in­for­ma­tion]
Kintor Pharma [9939.HK]
Two Ph3s on­go­ing in Chi­na: Piv­o­tal monother­a­py and com­bo with abi­raterone and a Ph2 on­go­ing in US for mCR­PC (with breast and other AR-driv­en can­cers be­hind). Ad­di­tio­n­al pipe­line in­cludes a top­i­cal AR for alope­cia and ear­li­er-stage tar­gets in­clud­ing ALK-1 and hedge­hog. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $175 MM MCap
Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
Longboard Pharmaceuticals [LBPH] $66 MM MCap
Fo­cused on de­vel­op­ing nov­el, trans­for­ma­tive medicines for neu­ro­log­i­cal dis­eas­es, with an ini­tial fo­cus on rare dis­eas­es. Long­board is cur­rent­ly eval­u­at­ing LP352, an oral, cen­tral­ly act­ing, next-gen­er­a­tion 5-hy­drox­ytryp­tamine 2c re­cep­tor su­per­a­g­on­ist, for the treat­ment of epilep­tic seizures. Long­board is al­so eval­u­at­ing a cann­abi­noid type 2 (CB2) re­cep­tor ag­on­ist for treat­ment of neu­rode­gen­er­a­tive dis­eas­es, and a sphin­go­sine-1-phos­phate (S1P) re­cep­tor mo­d­u­la­tor for treat­ment of neu­roin­flam­ma­to­ry dis­eas­es. [more in­for­ma­tion]
Marker Therapeutics [MRKR] $34 MM MCap
Fo­cused on de­vel­op­ing next-gen­er­a­tion T cell-based im­munother­a­pies for the treat­ment of he­ma­to­log­i­cal ma­lig­nan­cies and solid tu­mor in­di­ca­tions. Mark­er's cell ther­a­py tech­nol­o­gy is based on the se­lec­tive ex­pan­sion of non-en­gi­neered, tu­mor-spe­cif­ic T cells that rec­og­nize tu­mor as­so­ci­at­ed anti­gens and kill tu­mor cells ex­press­ing those tar­gets. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in RNA ac­ti­va­tion (RNAa). Tech­nol­o­gy ca­pa­ble of drug­ging any pro­tein tar­get to in­crease na­t­u­ral pro­tein pro­duc­tion in pa­tients own cells. Im­muno-on­col­o­gy and rare dis­ease pipe­line with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (on­go­ing ran­domized Ph2 in 2L HCC, Ph1/1b in ad­vanced solid tu­mors re­sis­tant to an­ti-PD1), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Modus Therapeutics AB [MODTX.SE]
Swedish biotech com­pany de­vel­op­ing the clin­i­cal stage as­set se­vu­parin, in­vent­ed at Karolin­s­ka In­sti­tutet, for dis­eas­es with high un­met med­i­cal need. The pre­sent fo­cus is to de­vel­op se­vu­parin for pa­tients with sep­sis/sep­tic shock, a se­vere and of­ten fa­tal con­di­tion. Se­vu­parin is a nov­el polysaccharide that acts by in­ter­fer­ing with the harm­ful agents gen­er­at­ed by white blood cells dur­ing sys­temic in­flam­ma­tion con­di­tions such as sep­sis. [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $389 MM MCap
Next-gen­er­a­tion molec­u­lar glue-based tar­get­ed pro­tein degra­da­tion plat­form de­vel­op­ing small molecule ther­a­peu­tics that se­lec­tive­ly de­grade dis­ease-caus­ing pro­teins. Tar­get­ing the un­drug­gable pro­teome in on­col­o­gy and non-on­col­o­gy in­di­ca­tions via AI based de­gron pre­dic­tion. Lead pro­gram fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of Myc-in­duced trans­la­tio­n­al ad­dic­tion. [more in­for­ma­tion]
Neogene Therapeutics
Neo­gene’s nov­el ap­proach in­tends to de­liv­er a tailored set of TCR genes for each in­di­vi­d­u­al pa­tient, which will be en­gi­neered in­to pa­tient-de­rived T cells di­rect­ing them to­ward neo-anti­gens in tu­mor cells, with the goal of pro­vid­ing a ful­ly in­di­vi­d­u­al­ized en­gi­neered T cell ther­a­py for can­cer. The Com­pany raised a $110M Se­ries A fi­nanc­ing co-led by EcoR1 Cap­i­tal, Jei­to Cap­i­tal and Syn­co­na, with par­ti­ci­pa­tion from Po­laris Part­n­ers, Pon­ti­fax, Seed in­ves­tors, Vi­da Ven­tures, TPG and Two Riv­er. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] $29 MM MCap
De­vel­ops next-gen­er­a­tion im­munother­a­pies for can­cer, in­flam­ma­tion and au­toim­mu­ni­ty us­ing de no­vo pro­tein de­sign tech­nol­o­gy. [more in­for­ma­tion]
NexImmune, Inc. [NEXI] $16 MM MCap
Mul­ti-anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Two Ph 1's on­go­ing. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Lead prod­uct, icos­abu­tate has been found safe and ef­fec­tive in two pri­or phase 2 clin­i­cal studies for treat­ment of hy­per­trig­lyc­eridemia and mixed dys­lipi­demia and is cur­rent­ly in clin­i­cal de­vel­op­ment for NASH. The icos­abu­tate phase 2b ICO­NA NASH trial is sche­d­uled to read­out in the first quar­ter of 2023. Two ad­di­tio­n­al SE­FAs are in clin­i­cal de­vel­op­ment; SE­FA 1024 is in phase 1 to be de­vel­oped for dys­lipi­demia and SE­FA 6179. [more in­for­ma­tion]
Novavax AB [NVAX] $1,463 MM MCap
Clin­i­cal-stage vaccine com­pany lev­er­ag­ing re­com­bi­nant nano­par­ti­cle tech­nol­o­gy plat­form to ad­dress a broad range of in­fec­tious dis­eas­es. NVX-CoV­2373, lead vaccine can­di­date against SARS-CoV-2 is be­ing eval­u­at­ed in two piv­o­tal Ph 3 trials [more in­for­ma­tion]
Nykode Therapeutics [NYKD:OL]
Ap­prox­i­mate $1.1B mar­ket cap, clin­i­cal stage im­munother­a­py com­pany fo­cused on can­cer and in­fec­tious dis­ease. Mo­d­u­lar vaccine tech­nol­o­gy tar­gets anti­gens to Anti­gen Pre­sent­ing Cells to achieve rapid, strong and long-last­ing im­mune re­spons­es. Key pro­grams in­clude Ph2 pro­pri­e­tary HPV 16+ cer­vi­cal can­cer ther­a­peu­tic vaccine, Ph2 in­di­vi­d­u­al­ized can­cer neoanti­gen vaccine (Ge­nen­tech), Ph1/2 next-gen­er­a­tion COVID-19 T-cell vaccines. Sig­ni­f­i­cant col­lab­o­ra­tions with Re­generon, Ge­nen­tech, Adap­tive Biotech­nolo­gies. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr2,394 MM MCap
Lead prod­uct Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC). Ap­proved in over 30 coun­tries, Hexvix®/Cysview® is di­rect­ly sold in the US and EU, and through world­wide part­n­er­ships. Pho­to­cure re­port­ed US$37.8M rev­enue in 2021 and ex­pects up to $250M from li­cense of non-core as­set CE­VI­RA® to Asieris. Head­quar­tered in Os­lo, Nor­way, Pho­to­cure is 20% owned by US in­ves­tors (sig­ni­f­i­cant in­crease over past few years) and com­mer­cial­ly fo­cused on US mar­ket. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] $86 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & IO. Phase 2a to­p­line da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma next year. Cash of $125MM in the bank as of Sept 2021. [more in­for­ma­tion]
Redx Pharma [REDX:L]
Dis­cov­ers and de­vel­ops nov­el tar­get­ed medicines for the treat­ment of can­cer and fi­brot­ic dis­ease. Lead on­col­o­gy as­set, Por­cu­pine in­hibi­tor RX­C004, com­menced Ph2 in 4Q21. RX­C004 al­so in Ph1 com­bi­na­tion with an­ti-PD-1 anti­body nivolumab. ROCK2 in­hibi­tor, RX­C007, in de­vel­op­ment for idio­path­ic pul­mo­nary fi­bro­sis, ex­pect­ing re­sults in 2022. £39.9M in cash. Cash run­way un­til end 2022. ~$1BN in po­ten­tial mile­s­tone rev­enues. Sup­port­ed by Red­mile Group, Soffi­no­va Part­n­ers, Po­lar Cap­i­tal [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] $197 MM MCap
Fo­cused on he­ma­to­log­ic di­s­or­ders, can­cer, and rare im­mune dis­eas­es. Rigel's first FDA ap­proved prod­uct is TA­VALISSE® (fos­ta­ma­tinib di­s­odi­um hex­ahy­drate) tablets, the on­ly oral spleen ty­ro­sine ki­nase in­hibi­tor for the treat­ment of chron­ic im­mune throm­bo­cy­tope­nia. The Com­pany is al­so tar­get­ing SYK in Warm Anti­body AI­HA and COVID-19, in­ter­leukin re­cep­tor-as­so­ci­at­ed ki­nas­es 1&4 in on­col­o­gy and im­mune dis­eas­es, and re­cep­tor-in­ter­act­ing serine/thre­o­nine-pro­tein ki­nase 1 in CNS dis­eas­es. [more in­for­ma­tion]
Savara Inc. [SVRA] $170 MM MCap
Clin­i­cal-stage bio­phar­ma fo­cused on rare re­s­pi­ra­to­ry dis­eas­es; mol­gra­mos­tim, an in­haled gran­u­lo­cyte-macrophage colony-sti­m­u­lat­ing fac­tor (GM-CSF), is in Phase 3 de­vel­op­ment for the treat­ment of au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP); top-line da­ta from the dou­ble-blind pe­ri­od of the Com­pany’s Phase 3 trial (IM­PALA 2) is an­ti­ci­pat­ed at the end of 2Q 2024. [more in­for­ma­tion]
Solebury Strategic Communications
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc. [SONN] $7 MM MCap
Uti­l­iz­ing a plat­form ap­proach to de­vel­op im­muno-on­col­o­gy ther­a­peu­tics fea­tur­ing a pro­pri­e­tary ful­ly hu­man Al­bu­min Bin­der ca­pa­ble of link­ing 1-2 dif­fer­ent ther­a­peu­tic tar­gets. Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. [more in­for­ma­tion]
Spruce Biosciences [SPRB] $32 MM MCap
Fo­cused on de­vel­op­ing and com­mer­cial­iz­ing nov­el ther­a­pies for rare en­docrine di­s­or­ders. The com­pany’s lead prod­uct can­di­date, Til­dac­er­font, is cur­rent­ly be­ing eval­u­at­ed for the treat­ment of clas­sic adult con­geni­tal adre­nal hy­per­pla­sia (CAH), and in up­com­ing studies in pe­di­a­tric clas­sic CAH and Po­ly­cys­tic Ovary Syn­drome (PCOS). [more in­for­ma­tion]
Sutro Biopharma [STRO] $306 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and other com­plex bi­o­log­ics for can­cer. The com­pany’s FolR&al­pha;-tar­get­ing ADC (STRO-002) in ovarian can­cer is cur­rent­ly in Ph 1 with dose-ex­pan­sion da­ta ex­pect­ed in 2H 2021. En­roll­ment is on­go­ing for CD74-tar­get­ing ADC (STRO-001) in the Ph 1 dose-es­ca­la­tion in B-cell ma­lig­nan­cies. Sutro has three high val­ue col­lab­o­ra­tions with BMS, Mer­ck, and EMD Serono. [more in­for­ma­tion]
Teon Therapeutics
Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]
The Oncology Institute Inc. [TOI] $356 MM MCap
TOI of­fers cutt­ing-edge, evi­dence-based can­cer care to a pop­u­la­tion of more than 1.5 mil­lion pa­tients in­clud­ing clin­i­cal trials, stem cell tran­s­plants, trans­fu­sions, and other care de­liv­ery mod­els tra­di­tio­n­al­ly as­so­ci­at­ed with the most ad­vanced care de­liv­ery or­gani­za­tions. With 80+ em­ployed clini­cians and more than 600 team­mates in 50 clin­ic lo­ca­tions and grow­ing, TOI is chang­ing on­col­o­gy for the bet­ter. [more in­for­ma­tion]
Treos Bio Limited
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
Vaccitech Plc [VACC] $122 MM MCap
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces CD8+ T cell and anti­body im­mune re­spons­es to treat and pre­vent in­fec­tious dis­eas­es and can­cer. Broad ther­a­peu­tic pipe­line. En­cour­ag­ing Ph1/2 in­ter­im ef­fi­ca­cy da­ta for VTP-300 (HBV func­tio­n­al cure) and VTP-200 (high-risk HPV ther­a­peu­tic) ef­fi­ca­cy da­ta ex­pect­ed 4Q2022. $15M roy­al­ty rev­enue dur­ing Q42021 from As­traZene­ca's com­mer­cial sales of Vaxzevria® (out-li­censed ChA­dOx COVID-19 vaccine) [more in­for­ma­tion]
Verrica Pharmaceuticals [VRCA] $117 MM MCap
A der­ma­tol­o­gy ther­a­peu­tics com­pany de­vel­op­ing med­i­ca­tions for skin dis­eas­es re­quir­ing med­i­cal in­ter­ven­tions. Ver­ri­ca's lead prod­uct can­di­date, VP-102, is a GMP-con­trolled for­mu­la­tion of can­tharidin de­liv­ered via a sin­gle-use ap­pli­ca­tor for the treat­ment of mol­lus­cum con­ta­gio­sum (mol­lus­cum), com­mon warts and ex­ter­nal geni­tal warts. The Com­pany is al­so de­vel­op­ing treat­ments for plan­tar warts (VP-103) and basal cell car­ci­no­ma (LTX-315). [more in­for­ma­tion]
Vivoryon [VVY:AS] €213 MM MCap
De­vel­ops small molecule medicines that mo­d­u­late the ac­tiv­i­ty and sta­bil­i­ty of patho­log­i­cal­ly al­tered pro­teins. Lead can­di­date varog­lu­tam­s­tat, cur­rent­ly in VIVI­AD EU Ph2b and VI­VA-MIND US Ph2a/2b studies in Alzheimer’s dis­ease (AD), tar­gets all three ma­jor hall­marks of AD (Abe­ta pathol­o­gy, tau pathol­o­gy, neu­roin­flam­ma­tion) and sy­nap­tic im­pair­ment. [more in­for­ma­tion]
XOMA Corporation [XOMA] $189 MM MCap
Biotech roy­al­ty and mile­s­tone ag­gre­ga­tor with port­fo­lio of 70+ as­sets in >30 dis­closed in­di­ca­tions where R&D costs are borne by part­n­ers e.g. Roche's Faricimab (BLA filed for nAMD and DME 7/29/21) [more in­for­ma­tion]
Zentalis [ZNTL] $1,265 MM MCap
De­vel­op­ing best-in-class small molecule ther­a­peu­tics tar­get­ing fun­da­men­tal bi­o­log­i­cal can­cer path­ways. Lead can­di­dates are ZN-c3, a Wee1 in­hibi­tor for ad­vanced solid tu­mors and ZN-d5, a BCL-2 in­hibi­tor for he­ma­to­log­ic ma­lig­nan­cies and re­lat­ed di­s­or­ders. Mul­ti­ple mono and com­bo trials are on­go­ing/planned across the pipe­line. [more in­for­ma­tion]